Ugandan biotech unveils sickle cell cure millions can afford.
At the weekend in Kampala, a piece of news landed that could reshape the future of one of the world’s most neglected diseases.The United States Patent and Trademark Office (USPTO) had accepted a groundbreaking patent from Dei BioPharma Ltd, a Ugandan biotechnology company led by scientist Dr Matthias Magoola.The innovation, approved on January 26, 2026, offers a radically different approach to treating sickle cell disease—one designed not only to cure the illness, but to make that cure affordable and accessible to the millions who need it most.
